ASO-driven optic nerve atrophy therapy — the targeted augmentation of nuclear gene output (TANGO) platform increasing OPA1 protein expression from the healthy allele representing the most clinically advanced approach in the global optic atrophy pipeline — creates the most commercially validated innovation segment, with the Optic Nerve Atrophy Treatment Market reflecting ASO technology as the near-term commercial driver.

The STK-002 mechanism — the intravitreal antisense oligonucleotide binding to nonsense-mediated decay exons on wild-type OPA1 pre-mRNA, preventing premature degradation and increasing stable mRNA abundance for translation into functional protein creating the protein restoration strategy. Preclinical primate data demonstrating dose-dependent OPA1 protein elevation four weeks post-injection persisting eight weeks, supporting the clinical dosing schedule.

Dosing and administration considerations — the need for repeated intravitreal injections (unlike one-time AAV gene therapy) creating the treatment burden versus flexibility trade-off. The OSPREY trial's sequential cohort, single ascending dose design evaluating safety and exposure through 2026-2027, with children requiring general anesthesia for intravitreal delivery adding procedural complexity and cost.

Competitive positioning — the ASO approach offering potential advantages over AAV gene replacement: no risk of insertional mutagenesis, ability to adjust dosing, established ophthalmic ASO delivery precedents, and reversible intervention creating the differentiated value proposition. However, the need for ongoing injections versus single-dose gene therapy creating the long-term patient compliance consideration.

Can ASO technology overcome the challenges of repeated intravitreal administration to become the standard of care for ADOA, or will one-time AAV gene replacement ultimately prevail?

FAQ How does TANGO technology work for ADOA? Mechanism: TANGO (Targeted Augmentation of Nuclear Gene Output) ASOs bind to specific exons in wild-type OPA1 pre-mRNA; this binding prevents nonsense-mediated decay of the mRNA transcript; result is increased stability, abundance, and concentration of wild-type OPA1 mRNA; higher mRNA available for translation produces more functional OPA1 protein; in haploinsufficient ADOA, this compensates for the 50% protein reduction caused by the mutant allele; restores mitochondrial fusion and cristae integrity in retinal ganglion cells; preclinical primate studies: dose-dependent OPA1 elevation at 4 weeks, sustained at 8 weeks; intravitreal delivery required. What are the advantages of ASOs over AAV gene therapy for optic nerve atrophy? ASO advantages: no permanent genetic modification (reversible); no risk of insertional mutagenesis; dose-adjustable; established delivery platform (intravitreal); can be stopped if adverse effects; no vector-related immune response; precedents in ophthalmology (e.g., nusinersen for spinal muscular atrophy). AAV advantages: single administration potentially curative; persistent expression; no need for repeated injections; may provide higher protein levels. Trade-offs: ASOs require ongoing treatment but offer safety flexibility; AAV offers convenience but carries irreversibility and immunogenicity risks. Both approaches in active clinical development. #OpticNerveAtrophy #ASO #GeneTherapy #ADOA #TANGO #Ophthalmology